化痰平喘方联合西药治疗慢性阻塞性肺疾病急性发作随机平行对照研究

Huatan Pingchuuan Method Combined with Western Side Treatment of Chronic Obstructive Pulmonary Disease Exacerbations Control Study

[目的]观察化痰平喘方联合西药治疗慢性阻塞性肺疾病急性发作疗效。[方法]使用随机平行对照方法,将60例住院及门诊患者按随机数字表法分为两组。对照组30例抗生素控制感染,盐酸氨溴索,6～12岁儿童,15mg/次,2～3次/d;2～6岁儿童,7.5mg/次,3次/d;2岁以下儿童,7.5mg/次,2次/d;均缓慢静滴。地塞米松,0.75～6mg/d,分2～4次服用,维持剂量0.5～0.75mg/d。治疗组30例化痰平喘方(茯苓20g,麻黄、桔梗各15g,半夏12g,瓜蒌20g,陈皮、杏仁、党参、山茱萸各15g),2剂/d,水煎200mL,早晚口服。西药治疗同对照组。观测临床症状、症状积分、不良反应。连续治疗2疗程,判定疗效。[结果]治疗组临床控制9例,显效12例,有效6例,无效3例,总有效率90.00%。对照组临床控制6例,显效11例,有效7例,无效6例,总有效率80.00%。治疗组疗效优于对照组(P<0.05)。症状积分两组均有改善,治疗组改善优于对照组(P<0.05)。[结论]化痰平喘方联合西药治疗慢性阻塞性肺疾病急性发作效果显著,值得推广。

[Objective]Observe Huatan Pingchuuan Method combined with western side treatment of chronic obstructive pulmonary disease,acute effects.[Methods]Using randomized controlled method,60 cases of outpatient and inpatient were randomly divided into two groups.Control group,30 cases of antibiotics to control infection,ambroxol,children aged 6 to 12,15mg / time,2 to 3 times / d;2 ～ 6 years old children,7.5mg / time,3 times / d;2 children,7.5mg / times,2 times / d;were slow intravenous infusion.Dexamethasone,0.75 ～ 6mg / d,2 to 4 times daily,maintenance dose of 0.5 ～ 0.75mg / d.Treatment group 30 cases Huatan Pingchuuan Method(Fuling 20g,Mahuang,Jugeng each 15g,Banxia 12g,Guawei 20g,Chenpi,Xingren,Dangshen,Shanzhuyu each 15g,2 does / d,decoction 200mL,sooner or later orally.Western medicine with the control group.Observation of clinical symptoms,symptom scores,adverse reactions.Continuous treatment of two courses(14d),to determine efficacy.[Results]The clinical control 9 cases,12 cases markedly effective in 6 cases,3 cases,the total efficiency of 90.00%.Six cases of clinical control group,11 cases markedly effective in 7 cases,6 cases,the total efficiency 80.00%.Treatment group than the control group(P<0.05).Symptom scores improved in both groups,the treatment group than the control group improved(P<0.05)[.Conclusion] phlegm and asthma combined with western side treatment of chronic obstructive pulmonary disease exacerbations effect is significant,worthy of promotion.